Abstract 1489P
Background
In light of the expanding utilization of electronic patient-reported outcomes (ePROs) in healthcare settings, their integration into the standard practice of palliative care remains uncertain. This investigation aimed to identify the determinants linked with adherence to ePRO utilization within a Cancer Network in Brazil.
Methods
Eligible patients had metastatic solid cancer with an expected survival of over 3 months. They were enrolled in monthly ePRO assessments using the Integrated Palliative Outcome Scale (IPOS). Patients failing to complete assessments received one reminder. We conducted multivariate regression analyses to examine the factors influencing adherence. Patient characteristics (age, gender, marital status, education level, and cancer type), along with initial responses on the IPOS, were included as predictors. Follow-up time within palliative care was controlled for in the analysis.
Results
A total of 494 patients were included, with a median age of 67 years (range: 22-94). Most were female (56.1%), married (58.9%), and had at least high school education (77.7%). Most were diagnosed with gastrointestinal (33.2%), breast (20.2%), and genitourinary (14.8%) cancers. Patients had a median follow-up time within palliative care of 10.5 months (range: 3-63 months). Notably, younger age (β=-0.3, SE=0.01, p=0.004), female gender (β=-0.7, SE=0.36, p=0.03) and higher education (β =0.1, SE = 0.06, p = 0.009) were associated with higher ePRO adherence. Interestingly, lower initial assessment score was linked with increased ePRO adherence (p=0.002). Patients experiencing loss of appetite (β=0.4, SE=0.18, p=0.01), having an anxious family member (β=0.3, SE=0.16, p=0.03), and expressing a desire for more information (β=0.2, SE=0.11, p=0.04) also demonstrated higher ePRO adherence.
Conclusions
Our findings underscore the need for tailored approaches to promote patient engagement and improve adherence to ePRO assessments in palliative care settings. Further research exploring interventions targeted at addressing these factors could enhance the integration of ePRO into routine clinical practice, ultimately leading to better patient outcomes and quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10